Breaking News

Biotech Consortium Launches KPI Therapeutics

June 5, 2014

Aims to speed drug development

A consortium of five biopharma firms and private investors have launched KPI Therapeutics, Inc. with the goal of speeding development of promising drug candidates. KPI research partners include MPI Research, Chimera Biotec, Life Chemicals, Medical Marketing Economics (MME), and Kineta, all of which are experienced in translational drug development.
 
KPI’s partners and investors will supply funding and expertise in an effort to make the early clinical drug validation process more efficient and to improve investor outcomes. Initially, KPI will focus on the most advanced projects within Kineta’s drug pipeline, and then intends to identify and advance programs from other industry sources.
 
KPI’s lead candidate, ShK-186, is a novel, immune-sparing therapeutic in Phase I development that has shown preclinical activity in psoriatic arthritis and other autoimmune diseases such as rheumatoid arthritis, lupus, multiple sclerosis, and asthma. KPI’s portfolio also includes compounds for antiviral and non-narcotic pain therapies.
 
“Despite recent advances in scientific knowledge and reports of promising new medicines from early stage discovery, we have not seen a concurrent surge in innovative therapies for patients reaching the market,” said Charles Magness, president and chief executive officer of Kineta and KPI board chairman. “KPI is designed to bring the capabilities of world-class drug development players and investors into a collaborative alignment where all patients, partners, and investors can benefit.”
 
Paul Sylvester, chief financial officer of MPI Research, a global CRO, and KPI board member, added, “We have enjoyed our existing partnership with Kineta and look forward to this new, expanded relationship, particularly because MPI Research is committed to supporting initiatives that build time and cost reductions into the drug development process.”
 

Related Contract Manufacturing:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.